<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9314">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985684</url>
  </required_header>
  <id_info>
    <org_study_id>ASD 15-04</org_study_id>
    <nct_id>NCT02985684</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs</brief_title>
  <acronym>ASSURED</acronym>
  <official_title>GORE® CARDIOFORM ASD Occluder Clinical Study: A Study to Evaluate Safety and Efficacy in the Treatment of Transcatheter Closure of Ostium Secundum Atrial Septal Defects (ASDs) - The Gore ASSURED Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of the GORE® CARDIOFORM ASD Occluder in the percutaneous
      closure of ostium secundum atrial septal defects (ASDs)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single-arm clinical study comparing outcomes with the
      GORE® CARDIOFORM ASD Occluder to performance goals derived from clinical investigation
      outcomes for devices indicated for ASD closure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-Month Closure Success</measure>
    <time_frame>6 months</time_frame>
    <description>Among subjects with technical success, the proportion of subjects with clinical residual defect status of occluded or clinically insignificant as determined by the Echo Core Lab at the 6-month evaluation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-Month Composite Clinical Success</measure>
    <time_frame>6 months</time_frame>
    <description>Among subjects with attempted study device closure, the proportion of subjects who satisfy all of the following components:
Technical Success: Successful deployment and retention at conclusion of index procedure of a GORE® CARDIOFORM ASD Occluder
Safety Success:
Freedom from any Serious Adverse Event (SAE) related to the device or procedure as adjudicated by the Independent Data Review Board (IDRB) through 30 days post-procedure
Freedom from device events (post-procedure embolization, device removal, or other device reintervention) from completion of the implant procedure through 6 months (180 days) post-procedure
Closure Success: A clinical residual defect status of occluded or clinically insignificant as determined by the Echo Core Lab at the 6-month evaluation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Atrial Septal Defect</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attempted implantation of GORE® CARDIOFORM ASD Occluder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® CARDIOFORM ASD Occluder</intervention_name>
    <description>Percutaneous Atrial Septal Defect Closure</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Appropriate ASD anatomy Note: Additional Inclusion Criteria may apply

        Exclusion Criteria:

          -  Absence of concurrent cardiac conditions that could elevate morbidity/mortality
             beyond what is common for ASD Note: Additional Exclusion Criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sommer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University of New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Gillespie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Aguilar</last_name>
    <phone>800-437-8181</phone>
    <email>haguilar@wlgore.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Sommer, MD</last_name>
      <phone>212-342-0886</phone>
      <email>rs2463@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Sommer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>November 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
